Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

NCT06999694 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma
Durvalumab
Tremelimumab
Proton Radiotherapy

Interventions

RADIATION: Proton radiotherapy
DRUG: Tremelimumab
DRUG: Durvalumab

Sponsor

Chang Gung Memorial Hospital